13:39 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on...
12:31 , Apr 12, 2018 |  BC Extra  |  Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on...
22:50 , Jan 5, 2018 |  BioCentury  |  Emerging Company Profile

Against radical pain

CerSci Therapeutics thinks that by neutralizing peroxynitrite and other free radicals it can treat acute pain and prevent it from becoming chronic, without the potential for abuse and addiction. CerSci was founded in 2014 to create...
19:53 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

AYX1: Ph II ADYX-004 started

Adynxx began the double-blind, placebo-controlled, U.S. Phase II ADYX-004 trial to evaluate single intrathecal injections of 660 mg AYX1 given prior to intrathecal administration of spinal anesthetic for unilateral total knee arthroplasty in about 200...
23:59 , Jan 10, 2017 |  BC Extra  |  Financial News

Adynxx raises $16M in series B

Pain company Adynxx Inc. (San Francisco, Calif.) raised $16 million in a series B round led by new investor TPG Biotech. Existing investor Domain Associates also participated. Adynxx said it plans to start a Phase II...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Target of EGR1 member 1 (TOE1)

Infectious disease INDICATION: HIV / AIDS Cell culture studies suggest TOE1 could help treat HIV. In a human cell-based assay of HIV transcription activity, TOE1 decreased transcriptional activation compared with no treatment. In human CD4+ T cells...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

AYX1: Phase IIb data

The double-blind, U.S. Phase IIb ADYX-003 trial in 120 patients who underwent knee replacement surgery showed that a single preoperative intrathecal injection of AYX1 plus standard of care (SOC) met the primary endpoint of reducing...
00:07 , Aug 12, 2015 |  BC Extra  |  Clinical News

Adynxx meets in pain relief Phase II

Adynxx Inc. (San Fransisco, Calif.) said AYX1 significantly reduced pain in a placebo-controlled Phase II trial to reduce acute and chronic pain. AYX1, a small synthetic dsDNA inhibitor of early growth response 1 ( EGR1),...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

AYX1: Completed Phase II enrollment

Adynxx completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase II ADYX003 trial evaluating single intrathecal injections of 660 and 1,100 mg AYX1 given prior to unilateral total knee replacement. Adynxx Inc., San...